Roivant Sciences | Investor Presentation Deck | 21 slides

Immunovant · 2022-09
arc beats above · slides in the middle · loops below · scroll → 0 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

1
coverage by narrative range · generated from this deck JSON
Narrative range 21 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Whole deck 21 slides 100% 21/21 slides 100% 21/21 slides · 76 hits
0/21 slides
42.9% 9/21 slides · 12 hits 14.3% 3/21 slides
0/21 slides
0/21 slides

Slide inventory

21
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
inspire_vision
04
The slide highlights the strategic advantage of IMVT-1402 building upon existing clinical validation of IgG lowering.present_solution
05
The slide uses a grid layout to categorize medical indications by therapeutic area (Neurology, Hematology, Endocrinology, Rheumatology, Renal, Dermatology).size_opportunity
06
establish_context
07
transition
08
The slide is partially obscured by a grey overlay, but the primary value proposition is clear.present_solution
09
The chart shows mean percent change from baseline with standard deviation bars.analyze_data
10
The slide contains three line charts with error bars representing mean ± SD.analyze_data
11
The slide uses molecular ribbon diagrams to illustrate binding site interference.present_solution
12
Includes financial runway disclosure in the footer.plan_implementation
13
transition
14
The slide uses a comparative layout to differentiate two products in the company's pipeline.present_solution
15
present_solution
16
The slide is mostly obscured by a grey overlay, but the title clearly indicates a strategic roadmap or development plan.plan_implementation
17
The table uses 'X' marks to indicate feature presence and specific clinical trial/dosing status for the Immunovant franchise.compare_peers
18
summarize
19
transition
20
The slide uses a color-coded legend to distinguish between trial initiation and data results for two different drug programs.plan_implementation
21
inspire_vision